Qorvo Biotechnologies granted emergency use authorization, awarded $24.4M contract, to produce COVID-19 rapid test

A new rapid antigen test that can identify whether a patient is COVID-19 positive in 20 minutes developed by Qorvo Biotechnologies has received emergency use authorization from the FDA, and the NIH awarded a $24.4 million contract to the company for its production.